Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.







26.05.2024, 1872 Zeichen

Marinomed: Marinomed Biotech AG (VSE:MARI) announces revenues of EUR 0.7 million recorded in the first quarter of 2024. After observing record revenues from Carragelose product sales heavily influenced by the SARS-CoV-2 pandemic over the past years, the revenue in the first quarter of 2024 has declined to levels observed before the pandemic. This decline is mostly due to high inventories and the return of seasonality, causing a drop in customer demand. Due to cost-conscious cash management, cash and cash equivalents stood at EUR 1.9 million compared to EUR 2.6 million at the end of 2023. The operating result (EBIT) stood at EUR -1.9 million (Q1 2023: EUR -1.4 million) and the loss for the period amounted to EUR -2.1 million (Q1 2023: EUR -2.1 million). “Although we are making constant progress and are working on several initiatives in parallel, the situation remains challenging. Revenues generated by the sales of Carragelose products will likely be characterized by the post-pandemic overhang of customers’ inventories and lower demand until the end of the year. Reaching an agreement with the EIB and real estate lenders to suspend repayments by 18 months has given us some more time and flexibility. At the same time, we have taken several measures to reduce the cash burn as much as possible”, Pascal Schmidt, CFO of Marinomed, adds. “However, closing deals with corresponding upfront and milestone payments for our Marinosolv assets remains our priority. At the same time, we are aiming for a decision regarding the evaluation of the whole Carragelose portfolio by the end of the first half of the year. We are optimistic that the cash flows generated from our efforts will be sufficient to cover our financing needs.”
Marinomed Biotech: weekly performance: -11.21%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (22/05/2024)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #679: Heute gleich 7 Austro-IPO-Geburtstage, wieviele wisst Ihr? Verbund nice, it´s fun to stay at the FACC


 

Bildnachweis

1. 21st Austria Weekly



Aktien auf dem Radar:Immofinanz, Warimpex, Addiko Bank, Austriacard Holdings AG, Semperit, Lenzing, Frequentis, Pierer Mobility, FACC, Wienerberger, Palfinger, Cleen Energy, SW Umwelttechnik, Oberbank AG Stamm, Amag, Agrana, CA Immo, Erste Group, EVN, Flughafen Wien, Österreichische Post, Polytec Group, Telekom Austria, Uniqa, VIG.


Random Partner

OeKB
Seit 1946 stärkt die OeKB Gruppe den Standort Österreich mit zahlreichen Services für kleine, mittlere und große Unternehmen sowie die Republik Österreich und hält dabei eine besondere Stellung als zentrale Finanzdienstleisterin.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner